Scott T. Guenthner M.D.
The Indiana Clinical Trials Center, PC
2155 E. Main Street, Suite 200
Plainfield, Indiana 46168
Phone: (317) 837-6082

PROFESSIONAL EXPERIENCE:

03/2006 – Present	President/CEO/Principal Investigator The Indiana Clinical Trials Center, P.C. Plainfield, Indiana
7/2002 – Present	Physician/President Dermatologist The Dermatology Center of Indiana, PC Plainfield, Indiana
6/1995 – 8/1995	Research Assistant College of Medicine Student Research Fellowship University of Iowa Iowa City, Iowa
1/1992 – 8/1994	Research Assistant Complement Laboratory University of Iowa Iowa City, Iowa

CERTIFICATION AND LICENSURE:

7/2002 - Present	Indiana Medical License #01051021
07/2002 -Present	NPI # 1396748778
11/2002 - Present	American Board of Dermatology
03/2009 - Present	Good Clinical Practice Certification

HOSPITAL AFFILIATIONS:

7/2002 – Present	Hendricks Regional Health Danville, Indiana
7/2002 – Present	St. Francis Hospitals and Health Services Indianapolis, Indiana
7/2003 – Present	Clarian West Medical Center Avon, Indiana
7/2004 – Present	St. Vincent Hospitals and Health Services Indianapolis, Indiana
10/2005- Present	Community Hospitals Indianapolis, Indiana

TEACHING EXPERIENCES:

2012 - Present	Physician / Dermatologist Mentor / Clinical Professor for Physician Assistant Students from Butler University, Multiple 1 - 4 week sessions with these students

11/4/2025

Updated 30OCT2025

2019 – Present	Physician / Dermatologist Mentor / Clinical Professor for Nurse Practitioner Students from George Washington University, 4-8 week sessions with these students

SPEAKING AND CONSULTING EXPERIENCES:

2014 – Present	Have given over 30 live and teleconference professional medical presentations to multiple audiences throughout Indiana and the United States for multiple pharmaceutical companies: Abbvie, Aclaris Pharmaceuticals, Allergan, Encore Dermatology, Janssen Pharmaceuticals, Sun Pharmaceuticals. These include local, regional, and national programs.
2015- Present	Have served on formal and informal multiple scientific advisory boards for the following companies: Abbvie, Aclaris Pharmaceuticals, Allergan, Encore Dermatology, Janssen Pharmaceuticals, Novartis, Sun Pharmaceuticals; Lead Investigator for Verrica Pharmaceuticals

VOLUNTEERING EXPERIENCES:

2017- 2018	Involved with supporting the National Psoriasis Foundation BINGO Night in Indianapolis

EDUCATION:

Graduated 5/1998	University of Iowa: Iowa City, Iowa Doctor of Medicine
Graduated 5/1994	University of Iowa: Iowa City, Iowa Bachelor of Science with Highest Distinction: Psychology

Honors:

Medical: President, Alpha Omega Alpha, Iowa Chapter, 1997
The Hancher-Finkbine Medallion, 1998
Undergraduate: Phi Beta Kappa, Junior Inductee, 1993
Cumulative GPA 4.0
University of Iowa Collegiate Scholar, 1994
Omicron Delta Kappa Province XI Leader of the Year, 1993-94
Boy Scouts of America - Eagle Scout with 2 palms, Earned at Age 14, Coordinated the construction of two welcome signs to the town of Tekamah, Nebraska, $4500 cost, over 250 combined adult and Scout volunteer hours.

Activities:

Medical: President, Medical Student Ambassador Program, 1996
Medical Student Council, 1995-1998
Student Preceptor, M1 Physical Examination Skills, 1997-1998
Undergraduate: Co-President, Phi Beta Kappa
General Council, Omicron Delta Kappa
Volunteer, Johnson County Big Brothers/Big Sisters Program

POSTGRADUATE TRAINING:

7/1999 – 6/2002	Indiana University: Indianapolis, Indiana Dermatology Residency

FELLOWSHIPS:

7/1998 – 6/1999	Transitional Internship St. Vincent Hospital and Health Services Indianapolis, Indiana

11/6/2025

MEMBERSHIPS/COMMITTEES:

7/2002 – Present University of Iowa Alumni Association Board of Directors

PROJECTS:

5/1999 **Indiana University Department of Dermatology**: Skin Cancer Education Project
Coordinated a skin cancer education project in which faculty and residents in the Department of Dermatology educated individuals of the community about melanoma and non-melanoma skin cancers at a local minor league baseball game.

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

Maves, KK, Guenthner, ST, et al. *Cloning and characterization of the cDNA encoding guinea pig properdin: a comparison of properdin from three species*. Immunology, 86 (3), 475-79, Nov. 1995

Guenthner, ST, Hurwitz, RM, Buckel, LJ, and Gray, HR. *Cutaneous Squamous Cell Carcinomas Consistently Show Histologic Evidence of In-Situ Changes: A Clinical-Pathological Correlation.* Journal of the American Academy of Dermatology, 41(3), 443-48, Sept. 1999.

Guenthner, ST, Hurwitz, RM, Buckel, LJ, and Gray, HR. *Cutaneous Squamous Cell Carcinomas Consistently Show Histologic Evidence of In-Situ Changes: A Clinical-Pathological Correlation.* Abstract, Journal of Cutaneous Pathology, 26 (9),465, Oct. 1999.

Guenthner, ST, Hurwitz, RM, Buckel, LJ, and Gray, HR. *Cutaneous Squamous Cell Carcinomas Consistently Show Histologic Evidence of In-Situ Changes: A Clinical-Pathological Correlation.* Poster Presentation. The American Society of Dermatopathology Annual Meeting, San Diego, CA, Nov 4-7, 1999.

Guenthner, ST, Draft, KS, and Hood, AF. Virtual Dermatology Case, Indiana University Department of Dermatology, May, 2000.

Piliang MP. Guenthner ST. Treadwell PA. *Abnormal hair growth in a child with atopy*. Archives of Dermatology. 137(11), 1521-6, Nov, 2001.

Jungers EA, Guenthner ST, Farmer ER, Perkins SM. *A skin cancer education initiative at a professional baseball game and results of a skin cancer survey.* International Journal of Dermatology. 2003 Jul; 42(7): 524-9.

Schaefer C, Cappelleri JC, Cole J, Guenthner S, Fowler J, Johnson S, Mamolo C. *Burden-of-Illness in Moderate-to-Severe Psoriasis Subjects Seeking Treatment: An Overall Descriptive Assessment.* Journal of Investigative Dermatology. Vol. 133. 2013.

Pariser, D, McConnehey, D, Matheson, R, Kempers, S, Guenthner, S, and Bukhalo, M. *A Phase 2 Study of Photodynamic Therapy (PDT) with Aminolevulinic Acid HCl (ALA) 20% Topical Solution + Blue Light vs ALA Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 & 3 Hours for the Treatment of Multiple Actinic Keratoses (A.K.) on the Face or Scalp.* Presented at the 71st Annual American Academy of Dermatology Meeting March 2013.

Pariser, D, McConnehey, D, Matheson, R, Kempers, S, Guenthner, S, and Bukhalo, M. *A Phase 2 Study of Photodynamic Therapy (PDT) with Aminolevulinic Acid HCl (ALA) 20% Topical Solution + Blue Light vs ALA Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 & 3 Hours for the Treatment of Multiple Actinic Keratoses (A.K.) on the Face or Scalp.* Journal of the American Academy of Dermatology, 68(4), AB156, April., 2013.

11/6/2025

Schaefer, CP, Cappelleri, JC, Cheng, R, Cole, JC, Guenthner, ST, Fowler, J, Johnson, S, and Mamolo, C. *Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States.* Journal of the American Academy of Dermatology, 73(4), 585-593, Oct., 2015.

Pariser, D, Houlihan, A, Ferdon, MB, et al. *Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp.* Dermatologic Surgery, 42(3), 296, Mar. 2016.

Pariser, D, Bukhalo, M, Guenthner, ST, Kempers, S, Shideler, S, Gold, LS, Tschen, E, Berg, J, Ferdon, MB, and Piacquadio, D. *Two multicenter, randomized, double-blind, parallel group comparison studies of halobetasol propionate lotion, 0.05% versus vehicle lotion in adult subjects with plaque psoriasis.* Journal of the American Academy of Dermatology, 74(5), AB280, May, 2016.

Simpson, Eric L., et al. *Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.* New England Journal of Medicine, 375(24), 2335-2349, Dec., 2016.

Pariser, D, Bukhalo, M, Guenthner, ST, Kempers, S, Shideler, S, Gold, LS, Tschen, E, Berg, J, Ferdon, MB, and Piacquadio, D. *Two multicenter, randomized, double-blind, parallel group comparison studies of halobetasol propionate lotion, 0.05% versus vehicle lotion in adult subjects with plaque psoriasis.* J Drugs Dermatol., 16(3), 234-240, Mar. 2017.

Travers, JB, Guenthner, ST, et al. *Quantifying Photodamage by Noninvasive Mesoscopic Skin Imaging.* Poster Presentation. The Ohio Dermatological Association Annual Meeting, Columbus, OH, Sept 7-9, 2018.

Tyring SK, Spelman L, Igarashi A, Ohtsuki M, Cichanowitz N, La Rosa C, Li Q, Mendelsohn AM, and Guenthner S. *Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 3-year results from reSURFACE 1.* Poster presentation. American Academy of Dermatology Annual Meeting, Washington D.C., USA, Mar 1–5, 2019.

Tyring SK, Spelman L, Igarashi A, Ohtsuki M, Mendelsohn AM, and Guenthner S. *Efficacy and Safety of long-term tildrakizumab for plaque psoriasis: 3-year results from reSURFACE 1.* Poster presentation. Academy of Managed Care Pharmacy Annual Meeting, San Diego, CA, USA, Mar 25–28, 2019.

Tyring SK, Spelman L, Igarashi A, Ohtsuki M, Li Q, Mendelsohn AM, Parson J, and Guenthner S. *Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1.* Poster presentation. Australasian College of Dermatologists Annual Scientific Meeting, Melbourne, Australia, May 18–21, 2019.

Tyring SK, Spelman L, Igarashi A, Ohtsuki M, Mendelsohn AM, and Guenthner S. *Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1.* Abstract submitted. Society of Dermatology Physician Assistants Annual Summer Dermatology Conference, Washington D.C., USA, Jun 6–9, 2019.

Tyring, SK, Guenthner, ST et. al. *Efficacy and Safety of Long-term Tildrakizumab for Plaque Psoriasis: 3-Year Results From reSURFACE 1.* Pending Publication - Journal of the American Academy of Dermatology, 2019.

Lebwohl, M, Blauvelt, A, Menter, A, Papp, K, Guenthner, S, Pillai, R, Israel, R, Jacobson, A. *Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.* American Journal of Clinical Dermatology. 20, 863-871, Nov. 2019.

11/6/2025

Schmeusser B, Borchers C, Travers JB, Borchers S, Trevino J, Rubin M, Donnelly H, Kellawan K, Carpenter L, Bahl S, Rohan C, Muennich E, Guenthner S, Hahn H, Ali Rkein, Darst M, Mousdicas N, Cates E, Sunar U and Bihl T. *Inter- and Intra-Physician Variation in Quantifying Actinic Keratosis Skin Photodamage.* Journal of Clinical & Investigative Dermatology. 8(2), Sept. 2020.

Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Chih-Ho Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonette R. *1% Q.D. for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials.* Poster Presentation. The Skin Disease Education Foundation Annual Dermatology Seminar. Las Vegas, NV. USA. Nov 20-21, 2020.

Shrager D, Guenthner S, et. al. *Baseline Characteristics of Atopic Dermatitis (A.D.) and A.D. Treatments in a Cohort of Adult A.D. Patients Initiating Dupilumab in a Real-World Registry (PROSE).* Poster Presentation. Revolutionizing Atopic Dermatitis Annual Conference. Virtual. December 13-14, 2020.

Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Chih-Ho Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonette R. *Tapinarof Cream 1% Q.D. for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials.* Poster Presentation. The Journal of Cutaneous Medicine WC21 Dermatology Conference. Jan 8, 2021.

Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Chih-Ho Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonette R. *Tapinarof Cream 1% Q.D. for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials.* Poster Presentation. Orlando Dermatology Aesthetic & Clinical Conference. Jan 14-17, 2021.

Blauvelt A, Farberg A, Sinclair R, Hanna S, Asahina A, Igarashi A, Guenthner S, Eads K, et. al. *5-year efficacy of tildrakizumab 100 and 200 mg in achieving and maintaining PASI 75/90/100 and PGA 0/1 in resurface 1 and 2.* Poster Presentation. Winter Clinical Dermatology Conference. Virtual. Jan 16-24, 2021.

Guenthner S, McFalda W, Tate M, Eads K, et. al.. *Phase 2 Safety and Efficacy of VP-102, a Drug-Device Combination Product Containing Cantharidin (0.7% w/v), for the treatment of External Genital Warts (Care-1).*

Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Hong Chih-ho, Soung J, Fromowitz J, Guenthner S, et. al. Tapinarof Cream 1% for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials. Pending Publication. New England Journal of Medicine. Mar 1, 2021.

Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Chih-Ho Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonette R. *Tapinarof Cream 1% Q.D. for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials.* Poster Presentation. Innovations in Dermatology 2021. Virtual. Mar 16-20, 2021.

Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Chih-Ho Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonette R. *Tapinarof Cream 1% Q.D. for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials.* Poster Presentation. Symposium for Inflammatory Skin Disease. Apr 9-11, 2021.

Blauvelt A, Sinclair R, Asahina A, Igarashi A, Mendelsohn A, Rozzo S, Eads K, Guenthner S, Guenthner L. *5-year efficacy of tildrakizumab 100 and 200 mg in achieving and maintaining PASI 75/90/100 and PGA 0/1 in resurface 1 and 2.* Poster Presentation. American Academy of Dermatology. Virtual. Apr 23-25, 2021.

Bhatia N, Bukhalo M, Guenthner S, Eads, K et. al.. *Microneedle lesion preparation prior to aminovulinic acid photodynamic therapy for actinic keratosis on the face.* Poster Presentation. The American Society for Laser Medicine and Surgery. Virtual. May 15-16, 2021.

11/4/2025

Lebwohl M, Stein Gold L, Strober B, Papp K, Armstrong A, Bagel J, Kircik L, Ehst B, Chih-Ho Hong H, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonette R. *Tapinarof Cream 1% Q.D. for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials.* Poster Presentation. San Diego Dermatology Symposium. Jun 11-13, 2021.

Matthew Zirwas, Zoe D. Draelos, Janet DuBois, Leon H Kircik, Angela Y. Moore, Linda Stein Gold, Javier Alonso -Llamazares, Michael Bukhalo, Suzanne Bruse, Kimmie Eads, Lawrence j. Green, Scott T. Guenthner, Laura k Ferris, Seth Forman, Steven E. Kempers, Edward Lain, Charles W. Lynde, David M. Pariser, Darryl P. Toth. Pau; S. Yamuchi, Amy Feng, Robert C. Higham, Patrick Burnett, David R. Berk *A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients with Moderate to Severe Seborrheic Dermatitis.* Poster Presentation 30th Congress of The European Academy of Dermatology and Venerology. Sept 29 – October 2, 2021.

Aleksandar Sekulic, Simon Yoo, Ragini Kudchadkar, Julie Guillen, Gary Rogers, Anne Lynn S. Chang, Scott Guenthner, Bernard Raskin, Keith Dawson, Yong Mun, Laura Chu, Edward McKenna, Mario Lacouture *Real-world assessment and treatment of locally advanced basal cell carcinoma: findings from the RegiSONIC disease registry.* RegiSONIC Baseline Manuscript Plos One. Sept 8, 2021.

Mark G. Lebwhol, Linda Stein gold, bruce Strober, Kim A. Papp, April W. Armstrong, Jerry Bagel, Leon Kircik, Benjamin Ehst, H Chih-ho Hong, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen C. Piscitelli, David S. Rubenstein, Philip M. Brown, Anna M. Tallman, Robert Bissonnette *Tapinarof Cream for Plaque Psoriasis: Results of Two Phase 3 Trials.* Manuscript New England Journal of Medicine. May 24, 2021.

Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris K, Jones T, Proulx S,9 R. Bissonnette, Bhatia N, Koppel R, Guenthner S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droege M, Berk D *The safety and efficacy of roflumilast cream 0·15% and 0·05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof-of-concept study.* British Journal of Dermatology Manuscript. November 17, 2021.

Teng J, Bunick C, Guenthner S, Murrell D, Marathe K, Kempers S, Kimmie Eads K, Mendelsohn A, Raiz J, Tavakkol A, Castelo-Soccio L *The CONTROL Study: Efficacy and safety of a novel topical isotretinoin formulation (TMB-001) for the treatment of recessive X-linked and autosomal recessive lamellar congenital ichthyos*is. Presented at the 2022 Winter Clinical Dermatology Conference Poster. January 14–19, 2022.

Murrell DF, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Bunick CG *Congenital ichthyosis subtype analysis of primary efficacy of a novel topical isotretinoin formulation (TMB-001): Results from the phase 2b CONTROL study in patients with recessive X-linked and autosomal recessive lamellar congenital ichthyosis.* Annual American Academy of Dermatology. Abstract. March 25–29, 2022.

Lebwohl M, Gooderham M, Guenthner S, Hong H, Kircik L, Moore A, Zirwas M, Feng A, Higham R, P Burnett P, Berk D *Pooled Efficacy and Safety Results from the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis.* American Academy of Dermatology (AAD) Annual Meeting Boston. Abstract. MARCH 25–29, 2022.

Lebwohl M, Gooderham M, Guenthner S, Hong H, Kircik L, Moore A, Zirwas M, Feng A, Higham R, P Burnett P, Berk D *Pooled Efficacy and Safety Results from the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis.* AMCP 2022 Chicago. Abstract. Mar. 29- Apr. 1, 2022.

Murrell D, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J,8 Bunick C *Congenital ichthyosis subtype analysis of primary efficacy of a novel topical isotretinoin formulation (TMB-001): Results from the Phase 2b CONTROL study in patients with recessive X-linked and autosomal recessive lamellar congenital ichthyosis. AAD. Abstract. 2022 .*

11/6/2025

Teng J, Castelo-Soccio L, Bunick C, Guenthner S, Kemper S, Eads K, Mendelsohn A, Raiz J, Murrell D, Marathe K *Efficacy of topical isotretinoin TMB-001 in children and adults with congenital ichthyosis: Phase 2b CONTROL study results.* The Society of Pediatric Dermatology (SPD) 2022 Meeting. Poster. June 21 2022

Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris L, MD, Jones T, Proulx E, Bissonnette R, Bhatia N, MD, Koppel R, MD, Guenthner S, MD, Eads K, Welgus H, Merritt C, MBA, Elias M, Navale L, Higham R, Droege M, Berk D *The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof-of-concept study.* Manuscript. JAAD. May 2, 2022.

Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L,Mendelsohn A, Raiz J, Murrell D *Characteristics of patients with congenital ichthyosis achieving greater than 50% reduction in Visual Index for Ichthyosis Severity scaling score relative to baseline after topical isotretinoin formulation TMB-001: CONTROL study results.* European Academy of Dermatology and Venereology (EADV) Meeting. Abstract. 2022.

Castelo-Soccio L, Teng J, Guenthner S, Marathe K, Kempers S, Eads K,Murrel D, Mendelsohn A, Raiz J, Bunick C *Change in quality-of-life measurements after treatment with topical isotretinoin formulation (TMB-001) at 12 weeks in patients with congenital ichthyosis at baseline: Phase 2b CONTROL study results.* European Academy of Dermatology and Venereology (EADV) Meeting. Abstract.2022.

Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Murrell D, Mendelsohn A, Raiz J, Bunick C *Effect of topical isotretinoin formulation (TMB-001) concentration on incidence of local skin reactions in patients with congenital ichthyosis: Phase 2b CONTROL study results.* European Academy of Dermatology and Venereology (EADV) Meeting. Abstract. 2022.

Marathe K, Teng J, Guenthner S, Bunick C, Kempers S, Eads K, Castelo-Soccio, L, Mendelsohn A, Raiz J, Murrell D *Effect of topical isotretinoin (TMB-001) treatment on laboratory parameters in patients with congenital ichthyosis: CONTROL study results* European Academy of Dermatology and Venereology (EADV) Meeting. Abstract. 2022.

Teng J, Bunick C, Guenthner S, Murrell D, Marathe K, Kempers S, Eads K, Mendelsohn A, Raiz J, Castelo-Soccio L *Efficacy and safety of topical isotretinoin (TMB-001) treatment in patients with X-linked recessive or autosomal recessive lamellar congenital ichthyosis: CONTROL study results*. European Academy of Dermatology and Venereology (EADV) Meeting. Abstract. 2022.

Teng J, Castelo-Soccio, L, Bunick C, Guenthner S, Kempers S, Eads K, Mendelsohn A, Raiz J, Murrell D, Marathe K *Efficacy of topical isotretinoin TMB-001 in children and adults with congenital ichthyosis: Phase 2b CONTROL study results*. European Academy of Dermatology and Venereology (EADV) Meeting. Abstract. 2022.

Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L,. Mendelsohn A, Raiz J, Bunick C *Congenital ichthyosis subtype analysis of primary efficacy of a novel topical isotretinoin formulation (TMB-001): Results from the Phase 2b CONTROL study in patients with recessive X-linked and autosomal recessive lamellar congenital ichthyosis*. European Academy of Dermatology and Venereology (EADV) Meeting. Abstract. 2022.

Bunick C, Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Mendelsohn A, Raiz J,Castelo-Soccio L *Change in Visual Index for Ichthyosis Severity after treatment with topical isotretinoin formulation TMB-001 in patients with congenital ichthyosis: CONTROL study results.* Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

11/6/2025

Marathe K, Murrell D, Teng J, Guenthner S, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C *Effect of topical isotretinoin formulation TMB-001 on percent BSA with ichthyosis relative to baseline in patients with congenital ichthyosis: results from the CONTROL study*. Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

Guenthner S, Marathe K, Bunick C, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D, Teng J *Improvement in IGA scores following treatment with topical isotretinoin (TMB-001) in patients with congenital ichthyosis: results from the CONTROL study.* Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

Bunick C, Teng J, Guenthner S, Marathe K , Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D *Proportion of patients with an IGA of cleared or almost cleared ichthyosis after treatment with topical isotretinoin formulation TMB-001 at 12 weeks: CONTROL study results.* Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

Teng J, Bunick C, Guenthner S, Murrell D, Marathe K, Kempers S, Eads K, Mendelsohn A, Raiz J, Tavakkol A, Castelo-Soccio L *The CONTROL study: A randomized, double-blind vehicle-controlled Phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis.* Manuscript JAAD. April 20,2022.

Forman S, Gutermuth J, Bruin-Weller M, Moore A, Guenthner S, Wolf E, Pierce E, Witte M, Zhong J, Wollenberg A *Lebrikizumab in Combination With Topical Corticosteroids Improves Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trial (ADhere).*Poster. Revolutionizing Atopic Dermatitis Conference (RAD); Baltimore, USA/Virtual. April 9-11 2022.

Zirwas M, Draelos Z, DuBois J, Kircik L, Moore A, Sein Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green L, Guenthner S, Ferris L, Forman S, Kempers S, Lain E, Lynde C, Pariser D,Toth D, Yamauchi P, Higham R, Feng A, Burnett P, Berk D. *Randomized, Double-blind, Vehicle-controlled Phase 2a Study of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis.* Manuscript. JAMA. March 10, 2022.

Lio P, Armstrong A, Guenthner S,Gutermuth J, Zhong J, Pierce E, Dawson Z, Witte M, Thyssen J, Wollenberg A *Lebrikizumab Improves Patient-Repprted Symptoms of Anxiety and depression in Moderate-to-Severe Atopic Dermatitis: Results From Three Randomized, Double-Blinded, Placebo- Controlled Phase 3 Trials.* Abstract. 12th Georg Rajka International Symposium on Atopic Dermatitis (ISAD). 2022.

Guenthner S, Rubin C, Marcoux D, Ramien M, Lynde C, Lee L, Assa A, Joyce J, Gupta R, Thomas R, Zhang A *The Impact of Moderate-to-Severe Atopic Dermatitis in Children Aged <12 Years in North America: An Analysis of the Real-World PEDISTAD Study.*SPD 2022. Abstract. July 7th-10th 2022.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study.* European Academy of Dermatology and Venereology (EADV), 10/28-11/1, 2020,virtual meeting. Oral Presentation.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study.* Society of Dermatology Physicians Assistants (SDPA) Fall Congress, 10/29-11/1, 2020, Miami, FL and virtual. Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study Fall Clinical Derm, 10/29-11/1, 2020, Las Vegas, NV and virtual.* Poster.

11/6/2025

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study Fall Clinical NP/PA, 11/13-15, 2020, virtual meeting.* Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. Skin Disease Education Foundation Las Vegas Dermatology Seminar (SDEF), 11/20-21, virtual meeting.* Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. Revolutionizing Atopic Dermatitis (RAD), 12/13-14, 2020, virtual meeting.* Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. Winter Clinical Dermatology Conference, 1/15-20, 2021, Las Vegas, NV and virtual.* Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. MauiDerm for Dermatologists, 1/25-29, 2021, Maui, HI and virtual.* Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. Innovations in Dermatology: Spring Conference, 3/16-20, 2021, virtual meeting.* Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. Symposium for Inflammatory Skin Disease (SISD) on 4/9-11, 2021, virtual meeting.* Poster.

Gooderham, Kircik, Zirwas, Lee, Kempers, Draelos, Ferris, Jones, St Cyr Proulx, Bissonnette, Bhatia, Guenthner, Koppel, Welgus, Merritt, Elias, Navale, Higham, Droege, Berk *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study. Dermatology Nurses' Association (DNA), 4/21-23, 2021, virtual meeting.* Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenthner, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. Maui Derm NP/PA Fall, 9/29-10/2, 2021, Asheville, NC and virtual.* Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenthner, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. Fall Clinical Derm, 10/21-24, 2021, Las Vegas, NV* Poster.

11/6/2025

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenthner, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. Derm Update Fall Meeting, Nov 11-13, 2021, Montreal, Canada.* Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenthner, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. Fall Clinical NP/PA, Nov 12-14, 2021, Orlando, FL.* Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenthner, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. Winter Clinical Dermatology Conference, 1/14-19, 2022, Koloa, HI.* Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenthner, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. MauiDerm for Dermatologists, 1/24-28, 2022, Maui, HI.* Poster.

Tyring SK, Spelman L, Igarashi A, Ohtsuki M, Mendelsohn AM, Guenthner S. *Efficacy and Safety of Long-term Tildrakizumab for Plaque Psoriasis: 3-year Results from reSURFACE* 1. Poster presented at: Society of Dermatology Physician Assistants 2019 Summer Conference; June 6-9, 2019; Washington, DC.

Tyring SK, Spelman L, Igarashi A, Ohtsuki M, Mendelsohn AM, Guenthner S. *Efficacy and Safety of Long-term Tildrakizumab for Plaque Psoriasis: 3-year Results from reSURFACE* 1. Poster presented at: International Dermatology Outcomes Measures Annual Meeting 2019; May 17-18, 2019; Washington, DC.

Sekulic A, Yoo S, Kudchadkar R, Guillen J, Rogers G, Chang ALS, Guenthner S, Raskin B, Dawson K, Mun Y, Chu L, McKenna E, Lacouture M. *Real-world assessment and treatment of locally advanced basal cell carcinoma*: RegiSONIC Disease Registry. 2022 Jan 14.

Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C. *Phase 2B randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis*. JEADV.

Guenthner S , Rubin C , Marcoux D , Ramien M ,Lynde C , Lee L, Assa'ad A , Joyce J , Gupta R, Thomas R, Zhangposter A. *The Impact of Moderate-to-Severe Atopic Dermatitis in Children Aged < 12 Years in North America: An Analysis of the Real-World PEDISTAD Study.* Presented at the 47th Annual Meeting of the Society for Pediatric Dermatology (SPD 2022); Indianapolis, IN, USA; July 7–10, 2022.

Elewski B, Han G, Rozzo S, Gogineni R, Schenkel B, Guenthner S. *Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analysis from the Phase 3 reSURFACE1 and reSURFACE2 trials.* American Academy of Dermatology Annual Meeting, March 17–21, 2023, New Orleans, LA.

11/6/2025

Rosso J, Guenthner S, Hong H, Jett J, Brown P, Rubenstein D, Piscitelli S.*Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application.* Fall Clinical 2022. Abstract.

Elewski B, Han G, Rozzo S, Gogineni R, Schenkel B, Guenthner S. *Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials.* AAD2023. Abstract.

Zirwas M, Draelos Z, DuBois, Kircik J, Moore A, Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green L, Guenthner S, Ferris L, Forman S, Kempers S, Lain E, Pariser D, Toth D, Yamauchi P, Higham R, Krupa D, Burnett P, Berk D, *Randomized, Double-blind, Vehicle-controlled Phase 2a Study of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis: A Randomized Clinical Trial.* JAMA Dermatology. Manuscript.

Guenthner S, Rubin C, Marcoux D, Ramien M, Lynde C, Lee L, Joyce J, Gupta R, Thomas R, Zhang A *The Impact of Moderate-to-Severe Atopic Dermatitis in Children Aged Less Than 12 Years in North America: An Analysis of the Real-World PEDISTAD.* Study encore poster at National Association of Pediatric Nurse Practitioners Conference; Orlando, FL. March 15-18, 2023.

Gooderham, Kircik, Zirwas , Mark Lee, Kempers, Draelos, Ferris, Jones T, Saint-Cyr Proulx E, Bissonnette R, Bhatia N, Koppel R, Guenthner S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droege M, Berk D. *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.* JDD. February 2012.

Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. *Characteristics and outcomes for participants with congenital ichthyosis. who responded to treatment with the topical isotretinoin formulation TMB-001: Results from the Phase 2b CONTROL study.* CED Manuscript.

Del Rosso J, Guenthner S, Hong C, Brown P, Rubenstein D, Piscitelli S. *Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application.* Winter Clinical 2023. Poster.

Del Rosso J, Guenthner S, Hong C, Brown P, Rubenstein D, Piscitelli S. *Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application.* Maui Derm 2023. Abstract

Del Rosso J, Guenthner S, Hong C, Brown P, Rubenstein D, Piscitelli S. *Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application.* Maui Derm 2023.Poster.

Bunick CG, Teng JMC, Guenthner S, et al. *Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clin Exp Dermatol.* 2023;48(7):765-769. doi:10.1093/ced/llad105

Zirwas MJ, Draelos ZD, DuBois J, Guenthner S, Eads K. *Efficacy of Roflumilast Foam, 0.3%, in Patients with Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.* JAMA Dermatol. 2023;159(6):613–620. doi:10.1001/jamadermatol.2023.0846

Kim B, Bissonnette R, Armstrong A, Pariser D, Guenthner S, Nograles K, Goncalves J, Cirulli J, Munera C, Smolen C, Lebwohl M. *Insights Into Baseline Demographics and Disease Characteristics in Subjects with Notalgia Paresthetica.* KOMFORT study on Baseline Disease Abstract, IDEOM 2023.

11/6/2025

Guenthner S, Rubin C, Marcoux D, Ramien M, Lynde C, Lee L, Assa'ad A, Joyce j, Gupta R. *The Impact of Moderate-to-Severe Atopic Dermatitis in Children Aged Less Than 12 Years in North America: An Analysis of the Real-World PEDISTAD Study.* encore poster at Pediatric Academic Societies Meeting; Washington DC, USA. April 27 – May 1, 2023.

Kim B, Bissonnette R, Armstrong A, Pariser D, Guenthner S, Nograles K, Goncalves J, Cirulli J, Muner C, Smolens C, Lebwohl M. *Insights Into Baseline Demographics and Disease Characteristics in Subjects With Notalgia Paresthetica.* Poster. IDEOM 2023

Sofen H, Tyring S, Johnson S, Guenthner S, Shannon P, Brown P, Tillman K, Fitzgerald N,Tallman A. *Efficacy of Tapinarof Cream 1% Once Daily for the Treatment of Mild to Severe Intertriginous Plaque Psoriasis. Abstract.* 2023 Fall Clinical Dermatology Conference

Sofen H, Tyring S, Johnson S, Guenthner S, Shannon P, Brown P, Tillman K, Fitzgerald N,Tallman A. *Tapinarof Cream 1% Once Daily Improves Patient-reported Outcomes in the Treatment of Mild to Severe Intertriginous Plaque Psoriasis.* Abstract. 2023 Fall Clinical Dermatology Conference

CLINICAL TRIAL EXPERIENCE:

2006–2006	COBRA Trial, Phase IV Trial of Clobex Spray for the Treatment of Plaque Psoriasis
2006–2019	APPLES Trial, Phase IV Study of Protopic Ointment Safety and Outcomes in the Treatment of Atopic Dermatitis
2006-2009	Phase IV Study of Raptiva Safety (RESPONSE)
2007-2008	Phase III Study of Raptiva in TNF- Alpha Biologic Failures
2007-2007	Phase III Study of Brand vs. Generic Benzaclin Gel Efficacy and Safety
2008-2008	Phase III Study of Brand vs. Generic Duac Gel Efficacy and Safety
2008-2010	Phase III Study of Raptiva Effectiveness for Scalp Psoriasis
2008-2009	Phase III Study of Brand vs. Generic Aldara Cream for the Treatment of Actinic Keratosis Efficacy and Safety
2008-2009	Phase III Study of Ingenol Mebutate Gel vs. Placebo for the Treatment of Actinic Keratosis Efficacy and Safety
2008-2009	Phase III Study of ABT-874 vs. Etanercept vs. Placebo for the Treatment of Moderate to Severe Plaque Psoriasis Efficacy and Safety
2008-2009	Phase III Study of Brand vs. Generic Protopic 0.1% for the Treatment of Atopic Dermatitis
12/2008-2023	A 10 year, post-marketing, observational, registry to assess long term safety of Humira (Adalimumab) in adult patients with chronic Plaque Psoriasis
2009-2009	Phase III Study of Brand vs. Generic Aldara Cream for the Treatment of Actinic Keratosis Efficacy and Safety
2009-2009	Phase IV Study, Open-label, 12-week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction with Oracea (doxycycline, USP) Capsules 40 mg (30mg immediate release and 10 mg delayed release beads) as Monotherapy or as Add-on Therapy to Existing Topical Regimens for the Treatment of Rosacea

SEG 11/6/2025

2009-2010	A Phase III, Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle Controlled Study to evaluate the Efficacy and Safety of PEP005 Gel, 0.015% in Patients with Actinic Keratosis ON the Head (Face or Scalp)
2006–2013	Phase IV Five-year Study of Enbrel Safety (OBSERVE)
2009-2012	Phase III Study of Alitretinoin vs. Placebo for the Treatment of Chronic Hand Eczema Efficacy and Safety
2009-2012	A Phase III, Multi-Center, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects which completed a preceding Psoriasis study with ABT-874
2009-2010	A 12 Month, Long Term Follow-up Study of Patients with Actinic Keratosis on the Head (face or Scalp) who have Completed the Day 57 in Studies PEP005-016 or PEP005-025
2009-2011	Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in patient with severe recalcitrant nodular acne
2010-2011	Phase III, A Double-Blind, Vehicle Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients with Moderate to Severe Plaque Psoriasis
2010-2012	Phase II, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris with Nodules
2010-2011	Phase III, A National, Multi-center, Prospective, Randomized, Double-Blind, 4-arm, Parallel Group, 8-week Study in Subjects with Psoriasis Vulgaris on the Non-Scalp Regions of the Body (trunk or limbs)
2010-2011	Phase III, A Randomized, Controlled Evaluation of the Safety and Efficacy of a Topical Treatment for Moderate- Severe Facial Acne Vulgaris
2011-2012	A Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream 3.75% And Zyclara (Imiquimod) Cream 3.75% In Subjects with Actinic Keratoses
2011-2012	A Multicenter, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% to Epiduo and Both Active Treatments to Placebo in the Treatment of Mild to severe Acne Vulgaris
2011-2012	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Study Comparing Metronidazole Topical Gel 1% to Metrogel 1% in the Treatment of Moderate to Severe Rosacea
2011-2012	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Rosacea-Specific Inflammatory Biochemical markers in the Skin of Adults with Papulopustular Rosacea Treated with Daily Doxycycline 40 mg (30 mg Immediate Release/10mg Delayed Release) capsules
2011-2012	A Phase II Study of Photodynamic Therapy with Levulun Topical Solution+ BLU light vs. Levulun Topical Solution Vehicle + BLU Light Using Spot and Broad Area Application and Incubation Times of 1,2, and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face and Scalp
2011-2012	An Evaluation of the Burden of Illness Among Adults in the United States with Moderate to Severe Plaque Psoriasis

11/6/2025

2012-2015	A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis
2012-2013	Phase 3 Randomized, Double-Blind, 12- week, Vehicle controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40- week investigator blinded extension comparing the long-term safety of CD5024 1% cream versus azelaic acid 15% gel
2012-2013	A Sequential Treatment Regimen of Cryotherapy and Picato (Ingenol mebutate) gel, 0.015% Field Therapy Compared to cryotherapy alone for the treatment of Actinic Keratoses on the Face and Scalp
2012-2015	A Phase 3B, Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate a "Subject Tailored" Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis-PSTELLAR
2012-2012	A Phase II Study Comparing Treatment with LEO 90100 with Betamethasone Dipropionate in LEO 90100 Vehicle and Calcipotriol in LEO 90100 Vehicle in Subjects with Psoriasis Vulgaris
2012-2012	A Phase II Study Comparing Treatment with LEO 90100 with Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects with Psoriasis Vulgaris
2012-2012	A Randomized, Double-Blind Placebo Controlled, 4-Week trial of IMO-3100 in Patients with Moderate to Severe Plaque Psoriasis
2012-2014	Randomized, Double-Blind, Vehicle-Controlled, Multicenter, parallel-Group Clinical Trials to assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 weeks in Subjects with papulopustular Rosacea
2012-2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Naftifine HCL Cream 1% to Naftin Cream 1% in the Treatment of Tinea Pedis
2012-2013	A randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Vehicle Controlled, Multicenter Study Comparing Imiquimod 3.75% to Zyclara
2012-2014	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose Escalating Study to Evaluate Coretexalone 17a-Propionate Once Daily or Twice Daily in Subjects with Facial Acne Vulgaris.
2012-2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Clindamycin 1%/ Benzoyl Peroxide 5% Topical Gel to Duac
2012-2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Diclofenac Sodium Gel 3% to Solaraze
2013-2013	A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris- Braintree
2013-2013	A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005% Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) with Plaque Psoriasis
2013-2014	A Double-Blind, Randomized, Parallel-Group, Vehicle Controlled, Multicenter Study Comparing TOLMAR Azelaic Acid Gel, 15% to Reference Listed Drug in the Treatment of Rosacea

11/26/2025

2013-2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Diclofenac Sodium Gel 3% to Solaraze
2013-2014	A Double-Blind, Randomized, Parallel Group, Vehicle-Controlled, Multicenter Study Comparing TOLMAR Naftifine HCl cream, 2% to Reference listed Drug in the treatment of Tinea Pedis
2013-2014	A randomized, Vehicle-Controlled, Double-blind, Parallel Group, Multi-center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis
2013-2015	A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-controlled Study to Evaluate the Safety and Efficacy and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference listed Finacea Gel 15% in patients with Moderate Facial Rosacea
2013-2015	A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritis
2013-2015	Safety and Efficacy of Escalating Doses of Ingenol mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on The Chest in Subjects with Actinic Keratosis
2013-2014	A Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5%, and Zyclara cream 2.5% in Subjects with Actinic Keratoses
2013-2015	A Randomized, Double-Blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2%/Benzoyl Peroxide 5% gel versus DUAC Gel versus Placebo in the ratio of 2:2:1 respectively in Patients with Acne Vulgaris
2013-2014	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis
2013-2019	A 64-Week, Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects with moderate-to-Severe Chronic Plaque Psoriasis
2013-2019	I1F-MC-RHBA (b): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
2014-2014	A randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis
2014-2015	A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris
2014-2014	A Randomized, Double-Blind, Multiple Site, Placebo-Controlled, Parallel Design Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo Topical Gel in the Treatment of Acne Vulgaris
2014-2015	A Phase 3 study of photodynamic therapy with Levulan Kerastick Topical solution + Blue light versus topical solution vehicle+ blue light for the treatments of actinic keratoses on the upper extremities

SAT 11/6/2025

2014-2015	Efficacy and Safety of Oxymetazoline HCl Cream 1.0% for the Treatment of Persistent Erythema Associated with Rosacea
2014-2015	A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab
2014-2015	Safety and efficacy of escalating doses of LEO 43204 applied once daily for two consecutive days on approximately 250 cm2 on trunk and extremities in subjects with actinic keratosis
2014-2016	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects with Chronic Plaque Psoriasis (CHS-0214-04) (Rapsody)
2014-2016	Twelve-Month Follow-up Evaluation of Subjects Participating in Dusa-CP0108 (A Phase 3 Study of Photodynamic Therapy with Levulan® Kerastick® Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
2014-2017	RegiSONIC: A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
2014-2017	A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
2014-2016	A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
2014-2016	A Multicenter Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
11/2014-2016	A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Incorporating Randomized Withdrawal and Retreatment
2015-2016	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Three Concentrations of Topically Applied BBI-4000 gel in Subjects with Axillary Hyperhidrosis
2015-2015	A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% Compared to Solaraze 3%, gel in the Treatment of Actinic Keratosis
2015-2015	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia (AGA)
2015-2016	A Phase 2 Study Comparing the Occurrence of Actinic Keratoses On the Face in High-Risk Individuals After Cryotherapy + Photodynamic Therapy with Levulan® Topical Solution + Blue Light Versus Cryotherapy + Vehicle Topical Solution + Blue Light
2015-2016	A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Foam 0.05% versus Vehicle Foam in Subjects with Plaque Psoriasis
2015-2016	A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis

11/6/2025

2015-2017	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis
2015-2016	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Fluorouracil Cream, 0.5% And Carac® (Fluorouracil) Cream, 0.5% In Subjects with Actinic Keratoses
2015-2016	A Multicenter, Randomized, Double-Blind, Vehicle controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.05% And Picato® Gel, 0.05% In Subjects with Actinic Keratosis on The Trunk or Extremities
2015-2016	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 in Subjects with Axillary Hyperhidrosis
2015-2016	An Open-Label Study Assessing Long-Term Safety of Drm04 In Subjects with Primary Axillary Hyperhidrosis
2015-2016	A Double-Blind, Randomized, Parallel-Group, Active Control Study to Compare the Efficacy and Safety of CHS-1420 Drug Product Versus Humira® in Subjects with Chronic Plaque Psoriasis
2014-2017	A prospective observational study of treatment patterns and effectiveness and safety outcomes in advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome patients.
2015-2017	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris
2015-2016	A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients
2015-2017	An Open-Label study of Dupilumab in Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
2015-2018	An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (isotretinoin) Capsules Administered Without Food in Subjects with Severe Recalcitrant Nodular Acne
2015-2018	An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (Cb-03-01) Cream, 1% Applied Twice Daily in Subjects with Acne Vulgaris
2015-2017	Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm^2 on the Chest
2015-2017	A Double-blind, randomized, placebo-controlled study, Evaluating the efficacy and safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
2015-2017	A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

11/6/2025

2015-2017	A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Access the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
2015-2017	A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects with Papulopustular Rosacea with a 4 Week Follow-up Period
2015-2017	A Multicenter, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study to Compare the Efficacy and Safety of CD5789 50µg/g Cream Versus Vehicle Cream in Subjects with Acne Vulgaris
2016-2017	A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and H.P. Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis
2016-2016	A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy with Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for Field Treatment of Actinic Keratoses on the Face
2016–2016	A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy With Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for the Field Treatment of Actinic Keratoses on the Face
2016-2016	A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Shampoo in Patients with Mild to Severe Scalp Psoriasis
2016-2016	A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy with Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for Field Treatment of Actinic Keratoses on the Face
2016-2016	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea
2016-2017	A Phase 2, Multicenter, Evaluator-Blinded Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IPD-118 Lotion with Tazorac ® (tazarotene) Cream, 0.05% in the Treatment of Plaque Psoriasis
2016-2017	BI 655066 versus Ustekinumab and placebo comparators in a randomized double-blind trial for Maintenance use in Moderate to severe plaque type psoriasis
2016-2018	BI 655066 versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment
2016-2018	A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea
2016-2017	A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

11/6/2025

2016-2017	A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
2016-2017	A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (azelaic acid) Foam, 15% in Patients with Moderate Facial Rosacea
2016-2017	A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Dose-Ranging, Study to Evaluate the Efficacy and Safety Profile of Pf-04965842 In Subjects with Moderate to Severe Atopic Dermatitis
2016-2017	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-Resistant Pruritus Associated with Atopic Dermatitis
2016-2017	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.015% And Picato® Gel, 0.015% In Subjects with Actinic Keratosis on The Face or Scalp
2016-2017	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 And Diclofenac Sodium Gel, 3% In Subjects with Actinic Keratoses
2016-2019	A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Plaque Psoriasis
2017-2018	A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing TOLMAR Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to Reference Listed Drug in the Treatment of Scalp Psoriasis
2017-2017	A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 5%, 10% and 15% Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects with Axillary Hyperhidrosis
2017-2018	A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
2017-2018	A phase 3, Multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO 1959 (Guselkumab) and secukinumab for the treatment of Moderate to Severe Plaque-Type Psoriasis
2017-2018	A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1 % Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults with Atopic Dermatitis
2017-2018	A Multicenter study of psorx lotion in subjects with moderate plaque psoriasis
2017-2018	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 versus Vehicle in Subjects 12 years of age or older with Cutaneous Common Warts
2017-2018	A Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied Once A Week in Subjects with Common Warts

11/6/2025

2017-2018	A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 weeks in the Treatment of Moderate - to - Severe Acne Vulgaris
2017-2018	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 To <18 Years of Age, With Moderate-To-Severe Atopic Dermatitis
2017-2018	A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison study to evaluate the safety and efficacy of UHE-101 cream 1% when applied twice daily for 12 weeks in subjects with facial acne vulgaris.
2017-2018	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib Ointment) in Subjects with Pruritus Associated with Psoriasis Vulgaris
2017-2018	A Randomized, Multicenter, Double-blind, Vehicle controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11)
2017-2018	A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis
2017-2019	A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp
2017-2019	A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of The Efficacy and Safety of Apremilast (Cc-10004) In Subjects with Moderate to Severe Plaque Psoriasis of The Scalp
02/2017-2020	Clinical Study Protocol M15-997: A multicenter, open Label study to assess the safety and efficacy of Risankizumab for maintenance in moderate to severe Plaque type Psoriasis (LIMITLESS)
04/2018-2020	an Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects with Atopic Dermatitis
04/2018-2020	Tralokinumab in combination with topical corticosteroids for moderate-to-severe atopic dermatitis ECZTRA 3 (Eczema Tralokinumab trial no. 3)
2018-2018	A Double-Blind, Randomized, Placebo-Controlled Exploratory Study to Assess the Efficacy and Safety of Tc-5214 In the Treatment of Subjects with Moderate to Severe Palmar Hyperhidrosis
2018-2018	A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and/or Multiple Intravenous and/or Subcutaneous Doses of PF-06817024 in Healthy Subjects Who May Be Mildly Atopic, Subjects with Chronis Rhinosinusitis with Nasal Polyps, and Subjects With Moderate to Severe Atopic Dermatitis
08/2018-2020	A Randomized, Double-Blind, Placebo Controlled, Efficacy Study of The Neurokinin-1 Receptor Antagonist Vly-686 In Patients With Atopic Dermatitis

AT
11/6/2025

08/2018-2020	A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of Pf-04965842 In Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis with The Option of Rescue Treatment in Flaring Subjects
08/2018-2025	A Prospective Observational Study of Adult Patients Receiving Dupixent For Atopic Dermatitis
09/2018-2020	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa
10/2018-2020	A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
10/2018-2020	A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis.
2018-2019	An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab In Patients Greater Than or Equal To 6 Months to Less Than 18 Years of Age with Atopic Dermatitis
2018-2019	A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study of Gbr 830 In Adult Subjects with Moderate to Severe Atopic Dermatitis
2018-2019	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab In Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
2018-2019	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Efficacy, Safety, Tolerability, And Pharmacokinetics of Asn002 In Subjects with Moderate to Severe Atopic Dermatitis
2018-2019	A Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects with Actinic Keratosis
2018-2019	A Multicenter, Randomized, Double-Blind, Placebo- Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
2018-2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects with Acne Vulgaris.
2018-2019	A Double-Blind, Randomized, Multicenter, Vehicle Controlled, Parallel Group Comparison Study to Determine the Efficacy and Safety of Halobetasol Propionate Spray, 0.05% Versus Vehicle Spray in Subjects with Plaque Psoriasis Receiving Up to Four Weeks of Twice Daily Treatment
2018-2019	A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects with Common Warts (Verruca Vulgaris)
2018-2019	An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)

11/6/2025

2018-2019	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
2018-2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
2018-2020	Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable.
2018-2021	A randomized, double-blind, placebo-controlled, parallel-group, multiple-site clinical study to evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream 1% (Taro Pharmaceuticals) to the market product ELIDEL (pimecrolimus) Cream 1% (Valeant Pharmaceuticals) in the treatment to mild to moderate Atopic Dermatitis.
10/2018-2022	A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis.
08/2018-2023	A Phase 3 Randomized, Double-Blind, Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of Pf-04965842, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis
1/2019-2020	A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
4/2019-2020	Phase IIa, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety, tolerability and efficacy of treatment with BI 655130 in adult patients with moderate to severe atopic dermatitis
6/2019-2020	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis
6/2019-2021	A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dost Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis
6/2019-2020	A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
6/2019-2021	A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults
6/2019-2021	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus
6/2019-2021	A Phase 3 randomized, double-blind, double-dummy, placebo-controlled, parallel group, multicenter study investigating the efficacy and safety of pf-04965842 and dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis
7/2019-2020	A Phase 2, Double Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts (EGW)

11/6/2025

8/2019-2021	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis
10/2019-2021	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
10/2019-2021	A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis
11/2019-2021	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis, who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment.
12/2019-2021	A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered Q.D. in Subjects with Chronic Plaque Psoriasis
12/2019-2021	A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered Q.D. in Subjects with Seborrheic Dermatitis
2019-2019	A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Urea Cream, 40% applied twice daily for 6 weeks in subjects with Ichthyosis Vulgaris
2019-2019	A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of Glycopyrronium Cloth, 2.4% in Patients with Palmar Hyperhidrosis
2019-2019	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Proof of Concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution with Occlusion in Subjects with Mild to Moderate Plaque Psoriasis
2019-2019	A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study FX2016-40)
2019-2019	A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and VehicleGel Once Daily in the Treatment of Molluscum Contagiosum
2019-2019	An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects ages 2 to 17 years with atopic dermatitis.
2019-2019	Phase 2 POC study of the safety and efficacy of ARQ-151 cream 0.05% and 0.15% administered Q.D. in adolescent and adult subjects with atopic dermatitis
2019-2021	A long-term, open-label, extension study to evaluate the safety and efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults.
3/2019-2023	An open-label, single-arm, multicenter, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials
2019-2023	A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of Bimekizumab in adult subject with moderate to severe Chronic Plaque Psoriasis

11/6/2025

2019-2022	A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
2019-2025	An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis.
2020-2021	A randomized, double-blind, placebo-controlled, multicenter, 16-week trial to evaluate the Efficacy and Safety of FB-401 in children, adolescent, and adult subjects (Ages 2 years and older) with mild to moderate Atopic Dermatitis.
2020-2021	A phase 2, multicenter, open-label study of the long-term safety of ARQ-154 Foam 0.3% in subjects with Seborrheic Dermatitis.
2020-2021	A phase 1 and 2, multiple dose and 12 week, parallel group, double blind, dose ranging, vehicle-controlled, study of the safety and efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in subjects with Chronic Hand Eczema.
2020-2021	A phase 2a, Proof of Concept, 24-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 Cream 0.3% in subjects with non-segmental facial vitiligo.
2020-2021	A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of CTP-543 in Adult patients with moderate to severe Alopecia Areata.
2020-2021	A phase 3, 16-week, randomized, double-blind, placebo-controlled, parallel-group study to assess the Impact of Lebrikizumab on vaccine responses in adult patients with moderate-to-severe Atopic Dermatitis.
2020-2021	A randomized, parallel, double-blind, vehicle-controlled study to evaluate the safety and efficacy of two concentrations of Topical TMB-001 for the treatment of Congenital Ichthyosis.
1/2020-2021	A phase 2a, randomized, double-blind, placebo- controlled, parallel group, multicenter study to investigate the mechanism of action of pf-04965842 monotherapy in adult participants with moderate-to-severe atopic dermatitis
2/2020-2021	A Randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab when used in combination with topical corticosteroid treatment in patients with moderate- to-severe atopic dermatitis
2/2020-2021	An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered Q.D. in Adolescent and Adult Subjects with Chronic Plaque Psoriasis
2/2020-2021	A double-blind, randomized, placebo-controlled study to assess the efficacy and safety of AT-5214 in the treatment of subjects with moderate to severe Palmar Hyperhidrosis
4/2020-2021	A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults with a History of Atopic Dermatitis
4/2020-2021	A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients with Non-Gorlin High Frequency BCC

11/6/2025

4/2020-2021	COVE-3: A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VP-102 in Subjects with Common Warts (Verruca Vulgaris)
2020-2022	An open label extension study to assess the long-term safety of treatment with BI 655130 administered subcutaneously in adult patients with moderate to severe atopic dermatitis.
2/2020-2022	A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered Q.D. in Adolescents and Adults with Scalp and Body Psoriasis
3/2020-2022	A randomized, double blind, placebo-controlled, multicenter, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable
4/2020-2022	A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa
2020-2024	A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in patients with moderate to severe Atopic Dermatitis.
2021-2021	A phase 3, 4-week, parallel group. Double blind, vehicle-controlled study of the safety and efficacy of a Cream Administered Q.D. in subjects with Atopic Dermatitis.
2021-2022	A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 FOAM 0.3% Administered Q.D. in Subjects with Seborrheic Dermatitis
2021-2022	A phase 2a/2b, Multicenter, Randomize, Placebo and Active Comparator-controlled, double-blind, dose-ranging study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the treatment of subjects with moderate to severe Hidradenitis Suppurativa.
2021-2022	A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
2021-2022	Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study: A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
2021-2022	A Phase 3, Open-label, Parallel Group, Multicenter, Extension Study Evaluating The Long-term Treatment of Bimekizumab In Study Participants With Moderate To Severe Hidradentis Suppurativa
2021-2022	A Phase 3, 8-week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered Q.D. in Subjects with Scalp and Body Psoriasis.
2021-2022	A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects with Notalgia Paresthetica
2021-2023	A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

11/6/2025

2021-2023	A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata.
2021-2023	A Phase 3 Efficacy and Safety Study to Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults.
2021-2024	A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis.
2021-2024	A Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis
2021-2024	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
2022-2022	A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients with Actinic Keratosis
2022-2022	A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of an Oral Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis
2022-2022	A Phase 2 Dose-finding Study to Evaluate the Efficacy, Safety, and Immunogenicity of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
2022-2023	A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa
2022-2023	PSoSA (PSOriasis Special Areas) - a US-based, Single Arm, Prospective, Multicenter, Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab
2022-2023	A Phase 2A, Open Label, PROOF-OF-CONCEPT TRIAL OF DAXDILIMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE ALOPECIA AREATA
2022-2023	A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
2022-2023	A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks
2022-2023	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects with Moderate to Severe Alopecia Areata
2022-2023	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study To Assess The Efficacy and Safety of Difamilast Ointment 1% In Children, Adolescents, And Adults with Mild to Moderate Atopic Dermatitis
2022-2024	The ASCEND Trial: A Multicenter, Double Blinded Vehicle Controlled Study of TMB-001, a Proprietary Isotretinoin Ointment, in the Treatment of RXLI (X-linked) or ARCI (Lamellar) Ichthyosis; Preceded by a Voluntary Maximal Use Study; Both Studies in Subjects 6 Years of Age and Above

SBB 11/6/2025

2022-2024	A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety and Tolerability of AMG 451 in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
2022-2024	A Multicenter, Open- Label Study to Assess the Long-term Safety of Difamilast Ointment 1% In The Treatment of Children, Adolescents, And Adults with Mild to Moderate Atopic Dermatitis
2022-2024	A Phase 2, Multicenter, Randomized, Double-Bling, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of VTX958 In Participants With Moderate To Severe Psoriasis
2022-2024	A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects with Atopic Dermatitis
2022-2024	A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis
2022-2025	Phase 3, 52-week Treat-through Study Evaluating AMG 451 Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)
2023-2023	A Phase 4, open-label study to investigate the efficacy and safety of VTAMA® (tapinarof) cream, 1 % in the treatment of plaque psoriasis in intertriginous areas
2023-2023	A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd.'s Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc's Zoryve (Roflumilast Cream 0.3%) and Both Active Treatments to a Vehicle Control in the Treatment of Chronic Plaque Psoriasis
2023-2023	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study To Evaluate The Efficacy and Safety of TDM-105795 In male Subjects With Androgenetic Alopecia
2023-2024	A Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
2023-2024	A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica
2023-2024	Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects with Atopic Dermatitis
2023-2024	A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults with Chronic Hand Eczema
2023-2025	An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
2023-2025	A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Parmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata
2023-2025	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa

2023-2025	A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris
2024-2024	A Double-blind, Randomized, Placebo-controlled, 3-Part Study Investigating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of BFB759 in Healthy Participants, Patients with Moderate-Severe Atopic Dermatitis, and Patients with Moderate-Severe Hidradenitis Suppurativa
2024-2025	A Phase 3 Study of Tolerability, Safety, and Efficacy of DMT310 in Patients with Acne Vulgaris
2024-2025	A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Non-Pustular Palmoplantar and Genital Psoriasis (Psoriatyk Special Sites)
2024-2025	A Phase 2a Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants with Moderate to Severe Atopic Dermatitis
2024-2025	Safety and Effectiveness of CGB-500 Topical Ointment with 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: A Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial
2025-2025	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Current Trials

09/2008-Present	A multicenter, open registry of patients with Psoriasis, who are candidates for systemic therapy, including biologics (PSOLAR)
2019-Present	A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata.
2021-Present	Inflammatory Skin Disease Treatment Identification Study (IDENTITY)
2023- Present	A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)
2023- Present	A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis
2023-Present	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate-to-Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment
2023-Present	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and safety of an Oral compound for the Treatment of Participants with Plaque Psoriasis with At Least Moderate Special Area Involvement
2024-Present	A clinical trial to evaluate the efficacy and safety of tralokinumab in adults subjects with atopic dermatitis and moderate-to-severe atopic hand eczema who are candidates for systemic therapy

11/6/2025

2024-Present	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2024-Present	A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa
2024-Present	A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
2024-Present	Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)
2024-Present	A randomized, double-blind, vehicle-controlled, multicenter Phase III study to evaluate the safety, tolerability, and efficacy of BF-200 ALA (Ameluz®) in the field-directed treatment of actinic keratosis on the extremities and neck/trunk with photodynamic therapy (PDT) using the BF-RhodoLED® XL or BF-RhodoLED® lamp.
2024-Present	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa – The CEDAR Study
2024-Present	A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
2024-Present	A Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of 3 subcutaneous dose regimens of lunsekimig (SAR443765) in adult participants with moderate-to-severe atopic dermatitis
2025-Present	A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects with Moderate to Severe Genital Psoriasis
2025-Present	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, MultiPart, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-1310 in Healthy Adult Volunteers, Patients with Atopic Dermatitis, and Patients with Chronic Pruritus
2025-Present	A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants with Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
2025-Present	A Phase 2b, Multicenter, Randomized Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Moderate to Severe Atopic Dermatitis
2025-Present	An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001 (ONWARD3)
2025-Present	A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Hidradenitis Suppurativa

11/4/2025

2025-Present	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects with Androgenetic Alopecia
2025-Present	Topical Ruxolitinib Evaluation in Hidradenitis Suppurativa (TRuE-HS2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
2025-Present	Open-label phase I study to evaluate the pharmacokinetics of 5-aminolevulinic acid and protoporphyrin IX in human plasma under maximal use conditions after topical application of 3 tubes of BF-200 ALA to a treatment field of 240 cm2 for photodynamic therapy (PDT) in subjects suffering from actinic keratosis in the periphery
2025-Present	A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa

I have signed my CV to acknowledge that it is accurate, complete, and current, as of the date of signing.

Signed: _____ Date: 11/6/2025